A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
Clinical trial NCT04919512 · COMPLETED
Trial details
- NCT number
- NCT04919512
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-07
- Primary completion
- 2025-02-04
- Enrollment
- 163
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.